Anti cd3 anti cd28 mab coated human t expander beads

Manufactured by Thermo Fisher Scientific

Sourced in United States

The Anti-CD3/anti-CD28 mAb-coated Human T-Expander beads are a cell culture tool used for the activation and expansion of human T cells. The beads are coated with monoclonal antibodies targeting the CD3 and CD28 receptors on T cells, which provides the necessary activation signals for T cell proliferation and differentiation.

Automatically generated - may contain errors

Lab products found in correlation

Cd3 microbeads, by Miltenyi Biotec (3 mentions) X vivo 15, by Lonza (2 mentions) Il 2 proleukin, by Novartis (1 mentions) X vivo 15 medium, by Lonza (1 mentions)

Spelling variants of this product

Anti-CD3/CD28 beads (199 citations) CD3/CD28 beads (82 citations) Anti-CD3/CD28 (45 citations) Anti-CD3/CD28-coated beads (33 citations) Anti-CD3/anti-CD28 beads (24 citations) Anti-CD3/anti-CD28-coated beads (22 citations) Anti-CD28 mAb (18 citations) Anti-CD3/CD28 mAbs (6 citations) MAb)-coated beads (3 citations) Anti-CD3/CD28 expander beads (2 citations)

3 protocols using anti cd3 anti cd28 mab coated human t expander beads

Anti-CD19 CAR T-cell Therapy for B-ALL

Check if the same lab product or an alternative is used in the 5 most similar protocols

All the donors of the 22 patients with B-ALL provided their peripheral blood
mononuclear cells (PBMCs) by hemapheresis for this anti-CD19-CAR T-cell therapy.
CD3+ T-cells were isolated by Ficoll density gradient centrifugation and elected
by CD3 microbeads (Miltenyi Biotec, Inc., Cambridge, MA, USA), then stimulated
by anti-CD3/anti-CD28 mAb-coated Human T-Expander beads (Cat. no. 11141D; Thermo
Fisher Scientific, Inc., Waltham, MA, USA) and cultured in T-cell medium X-Vivo
15 (Lonza Group, Ltd., Basel, Switzerland) supplemented with 250 IU/mL
interleukin-2 (IL-2; Proluekin; Novartis International AG, Basel, Switzerland).
All CD3+ T-cells (3 × 10⁶) of the 22 donors were transduced with
lentiviral vector encoding humanized CD19 CAR constructs (10 µg,
lenti-CD19-2rd-CAR, 4-1BB costimulatory molecule; Shanghai Genbase Biotechnology
Co., Ltd. Shanghai, China) and cultured in media containing recombinant human
IL-2 (250 IU/mL). On the 12th to 14th day of cultivation, transduction
efficiencies of anti-CD19-CAR were analyzed using FCM (BD Biosciences, San Jose,
CA, USA). Lymphodepletion chemotherapy comprised fludarabine (30
mg/m²) and cyclophosphamide (400 mg/m²) from day 4 to
day 2. All donor-derived anti-CD19-CAR T-cells were infused on day 0 (1 ×
10⁶ cells/kg) in patients with B-ALL.

Li Q., Lyu C., Liu M., Wang J., Mou N., Jiang E., Zhang R, & Deng Q. (2023). Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. Cell Transplantation, 32, 09636897231158155.

+ Open protocol

+ Expand

Generation of CD19-CAR T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs were collected and isolated by Ficoll density gradient centrifugation. CD3+ T cells were selected by CD3 microbeads (Miltenyi Biotec, Inc., Cambridge, MA, USA), stimulated by anti-CD3/anti-CD28 mAb-coated Human T-Expander beads (Cat. no. 11141D; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and cultured in T-cell medium X-Vivo 15 (Lonza Group, Ltd., Basel, Switzerland) supplemented with 250 IU/mL interleukin-2 (IL-2; Proleukin; Novartis International AG, Basel, Switzerland). All the CD3+ T cells (3 × 10⁶) were transduced with a lentiviral vector encoding humanized CD19 CAR constructs (10 μg, lenti-CD19-2rd-CAR; Shanghai Genbase Biotechnology Co., Ltd., Shanghai, CHINA) and cultured in media containing recombinant human IL-2 (250 U/ml). On the 12th day of cultivation, transduction efficiencies of anti-CD19-CAR were analyzed by flow cytometry (FCM) (BD Biosciences, San Jose, CA, USA).

Liu P., Liu M., Lyu C., Lu W., Cui R., Wang J., Li Q., Mou N., Deng Q, & Yang D. (2020). Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant. Frontiers in Oncology, 10, 573822.

+ Open protocol

+ Expand

Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells were collected from R/R MM patients and isolated by Ficoll density gradient centrifugation. CD3+ T cells were selected using CD3 microbeads (Miltenyi Biotec, Inc., Cambridge, MA, USA), stimulated by anti-CD3/anti-CD28 mAb-coated Human T-Expander beads (Cat. no. 11141D, Thermo Fisher Scientific, Inc., Waltham, MA, USA), and cultured in X-Vivo 15 medium (Lonza Group, Ltd., Basel, Switzerland) supplemented with 250 IU/ml interleukin (IL)-2 (Proleukin, Novartis International AG, Basel, Switzerland). CD3+ T cells (3 × 10⁶) were transduced with lentiviral supernatant from 293T cells transfected with anti-BCMA CAR plasmid (20 µg, lenti-BCMA-2rd-CAR, Shanghai Genbase Biotechnology Co., Ltd. Shanghai, China) at a multiplicity of infection of 0.5 and cultured in media containing IL-2 (250 U/ml). On the 12th to 15th days of cultivation, transduction efficiencies of anti-BCMA CAR were analyzed by flow cytometry (FCM) (BD Biosciences, San Jose, CA, USA).
All patients received lymphodepleting chemotherapy with fludarabine (30 mg/m²) and cyclophosphamide (400 mg/m²) from day −4 to day −2. Autologous anti-BCMA CAR T cells were infused on day 0 (2 × 10⁶ cells/kg) in all patients.

Deng H., Liu M., Yuan T., Zhang H., Cui R., Li J., Yuan J., Wang X., Wang Y, & Deng Q. (2021). Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Frontiers in Immunology, 12, 720571.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!